Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

JB Case, S Mackin, JM Errico, Z Chong… - Nature …, 2022 - nature.com
Omicron variant strains encode large numbers of changes in the spike protein compared to
historical SARS-CoV-2 isolates. Although in vitro studies have suggested that several …

Human-IgG-neutralizing monoclonal antibodies block the SARS-CoV-2 infection

J Wan, S Xing, L Ding, Y Wang, C Gu, Y Wu, B Rong… - Cell reports, 2020 - cell.com
Summary Coronavirus disease 2019 (COVID-19) has become a worldwide threat to
humans, and neutralizing antibodies have therapeutic potential. We have purified more than …

Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking

L Liu, RG Casner, Y Guo, Q Wang, S Iketani, JFW Chan… - Immunity, 2023 - cell.com
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …

[HTML][HTML] Dissecting strategies to tune the therapeutic potential of SARS-CoV-2–specific monoclonal antibody CR3022

C Atyeo, MD Slein, S Fischinger, J Burke, A Schäfer… - JCI insight, 2021 - ncbi.nlm.nih.gov
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
coupled with a lack of therapeutics, has paralyzed the globe. Although significant effort has …

Structural basis of SARS-CoV-2 and SARS-CoV antibody interactions

E Gavor, YK Choong, SY Er, H Sivaraman… - Trends in …, 2020 - cell.com
The 2019 coronavirus pandemic remains a major public health concern. Neutralizing
antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute …

Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209

B Ju, Q Zheng, H Guo, Q Fan, T Li, S Song, H Sun… - Cell Research, 2022 - nature.com
Dear Editor, Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and its variants is still a pandemic raging across the …

Structural basis of Omicron neutralization by affinity-matured public antibodies

DJ Sheward, P Pushparaj, H Das, C Kim, S Kim… - bioRxiv, 2022 - biorxiv.org
The SARS-CoV-2 Omicron Variant of Concern (B. 1.1. 529) has spread rapidly in many
countries. With a spike that is highly diverged from that of the pandemic founder, it escapes …

Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ. 1.1, CA. 3.1, CH. 1.1, XBB. 1.16, and XBB. 1.5

KC Entzminger, JK Fleming, PD Entzminger… - Antibody …, 2023 - academic.oup.com
Abstract SARS-CoV-2 Omicron variant XBB. 1.5 has shown extraordinary immune escape
even for fully vaccinated individuals. There are currently no approved antibodies that …

Structural study of SARS-CoV-2 antibodies identifies a broad-spectrum antibody that neutralizes the omicron variant by disassembling the spike trimer

W Zhan, X Tian, X Zhang, S Xing, W Song… - Journal of …, 2022 - Am Soc Microbiol
The continuous emergence of novel severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) variants poses new challenges in the fight against the coronavirus disease …

[HTML][HTML] Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies

F Muecksch, Y Weisblum, CO Barnes, F Schmidt… - BioRxiv, 2021 - ncbi.nlm.nih.gov
Antibodies elicited in response to infection undergo somatic mutation in germinal centers
that can result in higher affinity for the cognate antigen. To determine the effects of somatic …